Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile
暂无分享，去创建一个
R. Burgkart | J. Slotta-Huspenina | T. Haferlach | K. Götze | W. Kern | C. Peschel | S. Jilg | P. Jost | B. Schmidt | C. Müller-Thomas | N. Nadarajah | D. Hempel | Johanna Kauschinger | A. Jacob | Richard T Hauch | Ulrike Höckendorf | Veronika Reidel